Insider · SEC Form 4 filer
Vincent Angotti
Past buys: 2 of 5 beat
Companies
Where they file as an insider
Talphera (TLPH) CEO, Director Latest filing Apr 2, 2026
Track record
Did their buys beat the typical stock?
Open-market buys10
Quarters checked 6 months later5
Beat the typical stock 2 of 5
Quarters too new to check0
2 of 5 checked quarters beat the typical stock. A past record is data, not a forecast.
Talphera (TLPH) Bought Feb 12–Mar 13, 2026 · $211K · 318,674 shares Beat typical Mar 31, 2026 $0.75 → Sep 30, 2026 $1.16 · +55.3% (typical stock +1.7%)
Talphera (TLPH) Bought Apr 2, 2025 · $126K · 213,310 shares Beat typical Jun 30, 2025 $0.46 → Dec 31, 2025 $1.14 · +147.7% (typical stock +2.1%)
Talphera (TLPH) Bought Nov 27–Dec 5, 2024 · $6.85K · 10,000 shares Behind typical Dec 31, 2024 $0.52 → Jun 30, 2025 $0.46 · −12.2% (typical stock −3.4%)
Talphera (TLPH) Bought Aug 30, 2024 · $7.62K · 7,260 shares Behind typical Sep 30, 2024 $0.86 → Mar 31, 2025 $0.50 · −42.2% (typical stock −7.5%)
Talphera (TLPH) Bought Jun 12–14, 2024 · $9.84K · 10,000 shares Behind typical Jun 30, 2024 $0.89 → Dec 31, 2024 $0.52 · −41.1% (typical stock +3.9%)
Acelrx Pharmaceuticals (ACRX) Bought Dec 13, 2023 · $7.3K · 10,000 shares Not counted Not counted. We have no fund price for this stock on both Dec 31, 2023 and Jun 30, 2024.
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.